Given the three different MSH2 pathogenic variants characterized in our study, the tumor spectrum of confirmed MSH2 pathogenic carriers in the present study is similar to the one described in Western countries with the highest occurrence rates of CRC and EC (Dominguez-Valentin et al., 2020). This evidence concerns the gene MSH2 and neoplasm.